Current location:


Choose your location:

SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia


June 5, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.


BogotáBio, implementing an innovative collaboration model between the public and private sectors in the pharmaceutical sector in Bogota, aims to develop a range of vaccines that effectively address Colombia’s pressing need for immunization against various infectious diseases.


SINOVAC was selected by Bogota government as the winner among 15 biopharmaceutical companies invited globally through a tender process. The Company's extensive expertise and experience in vaccine R&D and production, and successful track record establishing vaccine manufacturing facilities will play a pivotal role in the new venture.


"BogotáBio will be one of the greatest innovations that we leave for Bogota in terms of research, development, and healthcare, said Claudia López, mayor of Bogota, as she described the new facilitys impact during the 2023 Smart City Expo Bogotá.


"It is our honor to serve as the exclusive strategic partner of the Bogota government in the esteemed BogotáBio project. The widespread use of our COVID-19 vaccine demonstrates the trust placed in us, and we sincerely appreciate it," said Helen Yang, Chief Business Officer of SINOVAC. "We should all learn from the experience of this pandemic. The collaborative project between the Bogota government and SINOVAC aims to establish the country's self-sufficient capability in rapidly developing and producing vaccines, with the objective of preventing or mitigating the impact of future infectious threats.


Colombia is one of the first countries in the world to adopt SINOVAC's COVID-19 vaccine, CoronaVac®, and granted emergency use approval for it in June 2021. To date, CoronaVac® and Healive®, SINOVACs hepatitis A vaccine, have been successfully distributed nationwide, effectively bridging the local vaccination gap with safe and affordable products.



Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.


For more information, please visit the Company’s website at



Sinovac Biotech Ltd. 

PR Team